Durmus, Pelin TasGorgulu, YaseminSonmez, Mehmet BulentCinar, Rugul Kose2024-06-122024-06-1220191018-86811309-5749https://doi.org/10.14744/DAJPNS.2019.00011https://search.trdizin.gov.tr/yayin/detay/323812https://hdl.handle.net/20.500.14551/19886Clozapine is a second-generation antipsychotic drug, proven to be effective in treatment-resistant schizophrenia. Among patients using clozapine; the incidence of neutropenia is approximately 3% and the incidence of agranulocytosis is approximately 1%. This side effect is diminishing after 18 weeks of drug initiation. Here, we present a case of clozapine-induced neutropenia in a schizophrenic patient seen after 7 years of clozapine use and its treatment with lithium supplementation.en10.14744/DAJPNS.2019.00011info:eu-repo/semantics/openAccessClozapineLithiumNeutropeniaColony-Stimulating FactorContinuing ClozapineRechallengeAgranulocytosisLeukopeniaArticle3217477N/AWOS:0004627318000112-s2.0-85064720930Q3323812